FDA says Novo Nordisk’s TV ad for obesity pill includes ‘false or misleading’ claims by CNBC Markets | February 9, 2026 11:09 pm | US Markets The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill.
